Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream inf ...
Reflections on the life and work of a remarkable writer, gardener, and teacher, from her friends and colleagues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback